



Types of Ulcerative Colitis, Pathogenesis of Ulcerative Colitis, Diagnosis of Ulcerative Colitis, Differential Diagnosis of Ulcerative Colitis and Treatment of Ulcerative Colitis.

Vaikunta Rao. V¹, Muralinath E.¹, Manjari P.¹, Sravani Pragna K.¹, KALYAN C.¹, Vinayasree. C², Guru Prasad M³, Venkat Navven. A,⁴ Sravani. K.⁵

¹College of Veterinary Science, Proddatur, Andhra Pradesh, India

2.. College of veterinary science, Korutla, PVNRTVU, Telangana, India.

3. Vaishnavi microbial Phama pvt.ltd, Hyderabad, India

4 Technical Sales Officer, Vijayawada, Andhra Pradesh, India

5.Veterinary Officer, Nuzivedu, Andhra Pradesh, India

ABSTRACT:

Ulcerative colitis (UC) is a chronic inflammatory bowel disease manifested by inflammation and ulceration of the mucosal lining of the colon and rectum. It is a multifactorial disorder that affects millions of people worldwide, causing significant morbidity and impairing the quality of life of patients. This review article aims to provide an in-depth analysis of the pathogenesis, clinical features, diagnosis, and treatment options available for ulcerative colitis. Through an extensive examination of current literature, we provide the information regarding understanding of the disease to aid doctors in managing UC effectively.

KEY WORDS: Ulceration of the mucosal lining of the colon as well as rectum, abdominal pain, rectal bleeding, weight loss, inflammation, ulcerative proctitis, proctosigmoiditis, trctal bleeding, tenesmus, bloody diarrhea, weight loss, fever, fatifue, abnormal immune response, dysbiosis, erythema nodosum, pyoderma, gangrenosum, sigmoidoscopy, CT angiography, colorectal cancer and ileosyomy.

I. INTRODUCTION

Ulcerative colitis (UC) is a form of inflammatory bowel disease (IBD) that primarily shows its effect on the colon and rectum. It is a chronic condition manifested by periods of remission and flare-ups, leading to symptoms namely abdominal pain, diarrhea, rectal bleeding, and weight loss. This article provides an information about pathogenesis of UC, its clinical manifestations, diagnostic approaches, and treatment strategies.

II. TYPES OF ULCERATIVE COLITIS

There are different types or classifications of ulcerative colitis dependent on the extent and location of the inflammation within the colon. The types of ulcerative colitis include:

Ulcerative proctitis

Proctosigmoiditis

Left-sided Colitis

Acute Severe Ulcerative Colitis

Ulcerative Proctitis:

This type of UC is limited to the rectum and is related to inflammation and ulcers only in the rectal area. Symptoms are rectal bleeding, tenesmus (feeling of incomplete evacuation), and urgency to pass stools.

Proctosigmoiditis:

In this type, inflammation spreads beyond the rectum and involves the sigmoid colon, which is the part of the colon right above the rectum. Symptoms are abdominal cramps, bloody diarrhea, and increased urgency to have bowel movements.

Left-sided Colitis:

This type of UC influences the left side of the colon, including the rectum, sigmoid colon, and the descending colon. Symptoms are abdominal pain, weight loss, bloody diarrhea, and sometimes fever.

Pancolitis:

Pancolitis involves inflammation that affects the entire colon, from the rectum to the cecum (the beginning of the colon). This type of UC can cause severe symptoms namely bloody diarrhea, abdominal pain, fatigue, weight loss, and fever.

Acute Severe Ulcerative Coliti


This is a severe and potentially life-threatening form of UC that affects the entire colon and develops rapidly. It results in dehydration, severe pain, and a significant risk of complications.

III. Pathogenesis

The exact cause of UC is not fully understood, but it is believed to result from a complex interplay of genetic, environmental as well as immune system factors. Here's an overview of the pathogenesis of ulcerative colitis:

Genetic Factors:

There is a significant genetic component to UC. Individuals with a family history of IBD, particularly first-degree relatives (parents, siblings, or children) with UC, exhibit an increased risk of developing the condition. Multiple genes have been involved in the susceptibility to UC, including the NOD2/CARD15 gene and the



interleukin genes (IL23R and IL10, for example).

Dys regulation of the Immune System:

One of the key elements in the pathogenesis of UC is an abnormal immune response. The immune system mistakenly identifies normal gut bacteria as foreign invaders, results in an exaggerated immune response. This leads to the occurrence of chronic inflammation of the intestinal lining.

Intestinal Barrier Dysfunction:

The intestinal lining behaves as a barrier between the gut and its contents along with bacteria. In individuals with UC, this barrier becomes compromised, permitting bacteria and other harmful substances to penetrate the lining and trigger an immune response.

Abnormal Immune Cell Activation:

Immune cells, such as T-cells, B-cells, and macrophages, infiltrate the gut lining and release pro-inflammatory cytokines. These cytokines are involved in the inflammatory process and further damage the intestinal tissue.

Environmental Triggers:

Environmental factors may play a critical role in causing or exacerbating UC in genetically susceptible individuals. Possible triggers are diet, infections, smoking, and stress.

Gut Microbiome:

The gut is home to a diverse community of microorganisms termed as the gut microbiome. In UC, there is an imbalance in the gut microbiome composition, with an enhancement in potentially harmful bacteria and a decrease in beneficial ones. This dysbiosis results in inflammations+ well as disease progression.

Epigenetic Modifications:

Epigenetic changes can influence gene expression without altering the underlying DNA sequence. Studies have shown that epigenetic modifications play a critical role in UC pathogenesis by influencing the regulation of immune-related genes.

Reactive Oxygen Species (ROS):

An enhanced production of reactive oxygen species within the intestinal lining can cause oxidative stress, leading to tissue damage and inflammation.

Neuroimmune Interactions:

The gut is also controlled by the enteric nervous system, sometimes referred to as the “second brain.” Dysregulation of neuro immune interactions results in the development of UC.

IV. Clinical Features

Its clinical features can vary in severity and presentation, but some common signs and symptoms are

Diarrhea:

Frequent and often bloody stools are a hallmark of UC. The severity of diarrhea can range from mild to severe.

Abdominal Pain and Cramping:

Patients with UC may exhibit abdominal discomfort and cramping, especially during bowel movements.

Rectal Bleeding:

Blood in the stool is a common symptom of UC. The color of the blood can vary, ranging from bright red to dark maroon.

Urgency to Defecate:

There is a strong, sudden urge to have a bowel movement, which can be challenging to control.

Tenesmus:

This is the sensation of urgency to pass stool even when the rectum is empty, leading to straining as well as discomfort.

Weight Loss:

Chronic inflammation and reduced absorption of nutrients can result in weight loss and malnutrition.

Fatigue:

UC can cause fatigue and weakness, likely due to inflammation and anemia (low red blood cell count) happened by rectal bleeding.

Fever:

In more severe cases of UC, patients may develop a fever, indicating systemic inflammation.

Loss of Appetite:

Reduced appetite is a common symptom of UC, related to abdominal discomfort as well as inflammation.

Anemia:

Chronic bleeding can lead to iron deficiency anemia, resulting in fatigue, weakness, and paleness.

Joint Pain:

Some people with UC may exhibit joint pain and swelling, resembling symptoms of arthritis.

Eye and Skin Problems:

Inflammatory conditions of the eyes (uveitis) and skin (erythema nodosum, pyoderma gangrenosum) can happen in association with UC.

V. DIAGNOSIS

The diagnosis of UC typically involves several steps:

Medical History:

The doctor will begin by taking a detailed medical history, including symptoms, family history of gastrointestinal diseases, and any relevant past medical conditions.

Physical Examination:

A physical examination will be conducted to check for signs of inflammation in the abdomen as well as rectal area.

Blood Tests:

Blood tests may be ordered to check for signs of inflammation, anemia, and other abnormalities.

Stool Sample:

A stool sample may be collected and analyzed to rule out infections and to check for any signs of inflammation or bleeding.

Colonoscopy:

Colonoscopy is a key diagnostic procedure for UC. During this procedure, a flexible tube with a camera on the end (colonoscope) is inserted through the anus to examine the entire colon and rectum. Biopsies (small tissue samples) may be collected during the colonoscopy to confirm the diagnosis and rule out other conditions.

Endoscopy:

In some cases, additional endoscopic procedures like sigmoidoscopy or flexible sigmoidoscopy may be performed to examine the lower part of the colon as well as rectum.

Imaging Tests:

Imaging tests such as CT scans or MRI may be ordered to obtain a better view of the gastrointestinal tract and assess the extent of inflammation.

Capsule Endoscopy:

In certain situations, a capsule endoscopy may be used. The patient swallows a small capsule with a camera inside, which takes pictures as it moves through the digestive system.

Histopathological Examination:

The biopsies taken during colonoscopy will be examined under a microscope by a pathologist to assess the presence of inflammation and other characteristic features of UC.

Other Tests:

Additional tests, such as upper endoscopy to examine for inflammation in the upper digestive tract, may be conducted if necessary.

It is essential to consult a qualified doctor for an accurate diagnosis and appropriate treatment plan. UC shares some symptoms with other gastrointestinal disorders, so the diagnosis process helps in distinguishing it from other conditions. Early diagnosis and management are critical in improving outcomes and quality of life for individuals with ulcerative colitis.

VI. DIFFERENTIAL DIAGNOSIS

Some conditions that may mimic or present similarly to Ulcerative Colitis include:

Crohn's Disease:

Another form of inflammatory bowel disease, Crohn's disease can affect any part of the gastrointestinal tract, whereas Ulcerative Colitis is limited to the colon and rectum. Crohn's Disease may also exhibit transmural inflammation, while Ulcerative Colitis is limited to the mucosal layer.

Infectious Colitis:

Caused by bacterial, viral, parasitic, or fungal infections and infectious colitis can result in inflammation and ulceration of the colon. Distinguishing between infectious and non-infectious colitis is critical for appropriate treatment.

Ischemic Colitis:

Reduced blood flow to the colon can result in ischemic colitis. Symptoms may overlap with Ulcerative Colitis, and imaging studies, such as CT angiography, can help differentiate the two conditions.

Diverticulitis:

Inflammation or infection of small pouches (diverticula) that can form in the colon can lead to symptoms similar to Ulcerative Colitis. Location and appearance on imaging can help differentiate between the two.

Microscopic Colitis:

This condition is manifested by chronic non-bloody diarrhea and microscopic inflammation of the colon lining, visible only under a microscope.

Irritable Bowel Syndrome (IBS):

IBS can result in abdominal pain, changes in bowel habits, and bloating. It is a functional disorder without evidence of inflammation observed in Ulcerative Colitis.

Celiac Disease:

An autoimmune disorder caused by gluten consumption, celiac disease can also cause chronic diarrhea and abdominal pain, but it primarily influences the small intestine, not the colon.

Inflammatory Bowel Disease Unclassified (IBDU):

In some cases, it might be challenging to definitively diagnose either Ulcerative Colitis or Crohn's Disease, leading to a diagnosis of IBDU.

Behçet's Disease:

A rare inflammatory disorder that can cause oral and genital ulcers, as well as gastrointestinal symptoms resembling Ulcerative Colitis.

Colorectal Cancer:

In some cases, colorectal cancer can present with symptoms similar to Ulcerative Colitis, making it responsible to rule out malignancy.

VII. TREATMENT

Treatment for ulcerative colitis (UC) depends on the severity of the disease and the individual's response to various therapies. It is typically related to a combination of medications and lifestyle changes. In some cases, surgery may be necessary if other treatments are not effective or if there are complications. Always consult a doctor for personalized advice, as they can plan the treatment to your specific needs. Here are some common treatment approaches for ulcerative colitis:

Medications:

a. Aminosalicylates:

These drugs decrease inflammation in the colon and are often used as a first-line treatment for mild to moderate UC.

b. Corticosteroids:

They are potent anti-inflammatory drugs used for short-term management of moderate to severe UC flare-ups.

c. Immuno modulators:

These medications suppress the immune system to help control inflammation and maintain remission in moderate to severe cases.

d. Biologics:

Biologic drugs target specific molecules participated in the inflammatory response and are used for moderate to severe UC when other treatments are not successful.

e. Janus kinase (JAK) inhibitors:

These medications prevent certain enzymes participated in the immune response and can be used for moderate to severe UC.

LIFESTYLE CHANGES:-

a. Dietary adjustments:

Certain foods may create flare-ups, so keeping a food diary and working with a dietitian can help identify and avoid trigger foods.

b. Stress management:

Stress can exacerbate UC symptoms, so finding stress-reducing techniques such as yoga, meditation, or counseling can be beneficial.

c. Regular exercise:

Staying physically active can help manage symptoms and improve overall well-being.

Supportive therapies:

a. Probiotics:

Some studies suggest that probiotics may help improve UC symptoms by promoting a healthy gut microbiome.

b. Pain management:

Over-the-counter pain relievers can help manage mild discomfort, but avoid nonsteroidal anti-inflammatory drugs (NSAIDs) as they can worsen UC symptoms.

Surgery:

If medications and other therapies fail to control UC or if there are severe complications namely massive bleeding, perforation, or cancer risk, surgery may be necessary. Surgical options include colectomy (removal of the colon) with or without ileostomy or ileoanal anastomosis.

It's essential for individuals with ulcerative colitis to work closely with a gastro enterologist or doctor to develop a tailored treatment plan and regularly monitor the condition. The goal of treatment is to induce and maintain remission, improve quality of life, and stop complications.

VIII. Emerging Therapies and Future Directions

This section examines ongoing research and potential novel therapies for UC, including targeted therapies, stem cell therapy, and microbiota-based interventions. Additionally, we explore the concept of personalized medicine and its potential impact on the management of UC in the future.

CONCLUSION

Ulcerative colitis is a complex and challenging disease that needs a multidisciplinary approach for optimal management. This review provides a comprehensive overview of UC, along with its pathogenesis, clinical manifestations, diagnostic tools, and treatment options. Doctors can use this information to enhance patient care,

promote early diagnosis, and develop novel therapeutic strategies to improve the lives of individuals living with UC.

REFERENCES OR FURTHER READING

- [1.] Gisbert JP, Chaparro M. Clinical Usefulness of Proteomics in Inflammatory Bowel Disease: A Comprehensive Review. *J Crohns Colitis*. 2019 Mar 26;13(3):374-384. [[PubMed](#)]
- [2.] Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. *Expert Rev Gastroenterol Hepatol*. 2018 Nov;12(11):1079-1100. [[PubMed](#)]
- [3.] Spiceland CM, Lodhia N. Endoscopy in inflammatory bowel disease: Role in diagnosis, management, and treatment. *World J Gastroenterol*. 2018 Sep 21;24(35):4014-4020. [[PMC free article](#)] [[PubMed](#)]
- [4.] Ashton JJ, Ennis S, Beattie RM. Early-onset paediatric inflammatory bowel disease. *Lancet Child Adolesc Health*. 2017 Oct;1(2):147-158. [[PubMed](#)]
- [5.] Liu CY, Polk DB. Microbiomes through the Looking Glass: What Do UC? *Cell Host Microbe*. 2018 Oct 10;24(4):472-474. [[PubMed](#)]
- [6.] Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. *Intest Res*. 2018 Oct;16(4):522-528. [[PMC free article](#)] [[PubMed](#)]
- [7.] Pai RK, Jairath V, Vande Casteele N, Rieder F, Parker CE, Lauwers GY. The emerging role of histologic disease activity assessment in ulcerative colitis. *Gastrointest Endosc*. 2018 Dec;88(6):887-898. [[PubMed](#)]
- [8.] Terry R, Chintanaboina J, Patel D, Lippert B, Haner M, Price K, Tracy A, Lalos A, Wakeley M, Gutierrez LS. Expression of WIF-1 in inflammatory bowel disease. *Histol Histopathol*. 2019 Feb;34(2):149-157. [[PubMed](#)]
- [9.] Yamamoto-Furusho JK, Fonseca-Camarillo G, Furuzawa-Carballeda J, Sarmiento-Aguilar A, Barreto-Zuñiga R, Martínez-Benitez B, Lara-Velazquez MA. Caspase recruitment domain (CARD) family (CARD9, CARD10, CARD11, CARD14 and CARD15) are increased during active inflammation in patients with inflammatory bowel disease. *J Inflamm (Lond)*. 2018;15:13. [[PMC free article](#)] [[PubMed](#)]
- [10.] Guardiola J, Lobatón T, Cerrillo E, Ferreiro-Iglesias R, Gisbert JP, Domènech E, Chaparro M, Esteve M, Rodríguez-Moranta F., en representación de GETECCU. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease. *Gastroenterol Hepatol*. 2018 Oct;41(8):514-529. [[PubMed](#)]
- [11.] Lee JS, Kim ES, Moon W. Chronological Review of Endoscopic Indices in Inflammatory Bowel Disease. *Clin Endosc*. 2019 Mar;52(2):129-136. [[PMC free article](#)] [[PubMed](#)]
- [12.] Rodríguez-Lago I, Ferreiro-Iglesias R, Nos P, Gisbert JP., en representación del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU). Management of acute severe ulcerative colitis in Spain: A nationwide clinical practice survey. *Gastroenterol Hepatol*. 2019 Feb;42(2):90-101. [[PubMed](#)]
- [13.] Borman ZA, Côté-Daigneault J, Colombel JF. The risk for opportunistic infections in inflammatory bowel disease with biologics: an update. *Expert Rev Gastroenterol Hepatol*. 2018 Nov;12(11):1101-1108. [[PubMed](#)]
- [14.] McKenna NP, Bews KA, Behm KT, Mathis KL, Lightner AL, Habermann EB. Do Patients With Inflammatory Bowel Disease Have a Higher Postoperative Risk of Venous Thromboembolism or Do They Undergo More High-risk Operations? *Ann Surg*. 2020 Feb;271(2):325-331. [[PubMed](#)]
- [15.] Willian MK, D'Haens G, Yarlus A, Joshi AV. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study. *J Patient Rep Outcomes*. 2018 Dec;2:22. [[PMC free article](#)] [[PubMed](#)]
- [16.] Drews JD, Onwuka EA, Fisher JG, Huntington JT, Dutkiewicz M, Nogalska A, Nwomeh BC. Complications after proctocolectomy and ileal pouch-anal anastomosis in pediatric patients: A systematic review. *J Pediatr Surg*. 2019 Jul;54(7):1331-1339. [[PubMed](#)]